GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Change In Payables And Accrued Expense
中文

Oncodesign Precision Medicine (XPAR:ALOPM) Change In Payables And Accrued Expense

: €0.00 Mil (TTM As of Jun. 2022)
View and export this data going back to 2022. Start your Free Trial

Oncodesign Precision Medicine's Change In Payables And Accrued Expense for the quarter that ended in Jun. 2022 was €0.00 Mil. It means Oncodesign Precision Medicine's Accounts Payable & Accrued Expense stayed the same from Dec. 2021 to Jun. 2022 .

Oncodesign Precision Medicine's Change In Payables And Accrued Expense for the fiscal year that ended in Dec. 2021 was €0.00 Mil. It means Oncodesign Precision Medicine's Accounts Payable & Accrued Expense stayed the same from Dec. 2020 to Dec. 2021 .

Oncodesign Precision Medicine Change In Payables And Accrued Expense Historical Data

The historical data trend for Oncodesign Precision Medicine's Change In Payables And Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
Change In Payables And Accrued Expense
- -

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
Change In Payables And Accrued Expense - - -

Oncodesign Precision Medicine Change In Payables And Accrued Expense Calculation

Change In Payables And Accrued Expense is the increase or decrease between periods of the Accounts Payable & Accrued Expense. Accrued expenses represent expenses incurred at the end of the reporting period but not yet paid; also called accrued liabilities. The accrued liability is shown under Liabilities section in the balance sheet.

Change In Payables And Accrued Expense for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was €0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine Change In Payables And Accrued Expense Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Change In Payables And Accrued Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Change In Payables And Accrued Expense
Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines